Corpus ID: 10743554

CDK 6 protects Epithelial Ovarian Cancer from platinum-induced death via FOXO 3 regulation

  title={CDK 6 protects Epithelial Ovarian Cancer from platinum-induced death via FOXO 3 regulation},
  author={Alessandra Dall’Acqua and Maura Sonego and Ilenia Pellizzari and Ilenia Pellarin and Vincenzo Canzonieri and Sara D'Andrea and Sara Benevol and Roberto Sorio and Giorgio Giorda and Daniela Califano and Marina Bagnoli and Loredana Militello and Delia Mezzanzanica and Gennaro Chiappetta and Joshua Armenia and Barbara Belletti and Monica Schiappacassi and Gustavo Baldassarre},
Epithelial ovarian cancer (EOC) is an infrequent but highly lethal disease, almost invariably treated with platinum-based therapies. Improving the response to platinum represents a great challenge, since it could significantly impact on patient survival. Here, we report that silencing or pharmacological inhibition of CDK6 increases EOC cell sensitivity to platinum. We observed that, upon platinum treatment, CDK6 phosphorylated and stabilized the transcription factor FOXO3, eventually inducing… Expand

Figures from this paper

USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability
It is reported that the ubiquitin-specific protease 1 (USP1) mediates ovarian cancer cell resistance to platinum, by regulating the stability of Snail, which, in turn, promotes tumor dissemination. Expand
Clinical significance of microRNA-449a in hepatocellular carcinoma with microarray data mining together with initial bioinformatics analysis
The aim of the present work was to systematically review the current literature and to utilize the public Gene Expression Omnibus database to determine the role of miR-449a and its significance in HCC. Expand
CDK6 3'UTR polymorphisms alter the susceptibility to cervical cancer among Uyghur females
The aim of this study was to evaluate the effects of CDK6 3' untranslated region (3'UTR) polymorphisms on cervical cancer susceptibility among Uyghur females. Expand
An integrative multi-omics network-based approach identifies key regulators for breast cancer
Graphical abstract


The Role of CDK4/6 Inhibition in Breast Cancer.
This review outlines the development of CDK inhibitory therapy in breast cancer, including the initial experience with the pan-CDK inhibitor flavopiridol and the next generation of oral highly selective CDK4 and CDK6 inhibitors, and describes the application of such therapy to other breast cancer settings. Expand
Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells
Three new models of platinum-resistant isogenic EOC cell lines are established and it is suggested that GEP studies alone, at least when performed under basal culture condition, do not represent the optimal way to identify molecular alterations linked to DNA repair pathway defects. Expand
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
PD-0332991 shows promising biologic activity in ovarian cancer cell lines, and assessment of Rb and p16 expression may help select patients most likely to benefit from CDK4/6 inhibition in Ovarian cancer. Expand
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis
It is suggested that blockage of VEGF through the use of an anti-VEGFA antibody may not be sufficient to improve survival in ovarian cancer patients unless VEGFB signaling is also blocked. Expand
Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer
The hypothesis that the expression of stathmin and p53 could be useful for the identification of high risk patients that will benefit from a therapy specifically acting on mitotic cancer cells is supported. Expand
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
The results of the present study confirm CDK4/6 inhibition by PD0332991 at a well-tolerated dose and schedule and suggest clinical benefit in a subset of MCL patients. Expand
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
The present data support a possible role for CDK4/6 inhibitors in a majority of patients with advanced cancer and suggest statistically significant protection of platelets in tumor-bearing mice. Expand
A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.
The Forkhead Box M1 (FOXM1) transcription factor is identified as a common critical phosphorylation target for CDK4/6 inhibition and its role in maintaining expression of G1/S phase genes, suppress the levels of reactive oxygen species (ROS), and protect cancer cells from senescence is identified. Expand
Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors
New data demonstrate that cdks are ‘master’ regulators of DNA damage checkpoint and repair pathways, and cdk inhibition may provide a means of potentiating the clinical activity of DNA-damaging chemotherapeutic agents for the treatment of cancer. Expand
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
  • M. Dickson, W. Tap, +11 authors G. Schwartz
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
Treatment with theCDK4 inhibitor PD0332991 was associated with a favorable progression-free rate in patients with CDK4-amplified and RB-expressing WDLS/DDLS who had progressive disease despite systemic therapy. Expand